Please login or register to print this page.

ARTICLE CONTRIBUTORS

European Society of Cardiology

Clinical Articles, News & Views

ESC Congress 2014 focuses on innovations in cardiology

The European Society of Cardiology (ESC) Congress 2014 promises to be bigger, better and more interactive than ever before, says Professor Keith Fox, Chair of the Congress Programme Committee. Record numbers of Hot Line sessions and abstracts were submitted this year and the congress is on track to host the largest number of delegates in its history, according to the statement.

Asked why an extra hot line session has been added this year, with 27 presentations in total, Professor Fox said: “We have an abundance of riches, with an all time high of 247 hot line and clinical trial update submissions. These hot lines are embargoed, and many will appear in the major journals so I can’t talk about any results. But I know just from the topics that there is a huge amount of interest.”

PARADIGM-HF (This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure) will begin the hot line sessions by comparing the impact of gold standard treatment with an ACE inhibitor to a new angiotensin receptor blocker-neprilysin inhibitor (ARNI) on mortality and morbidity. The trial was stopped early for a benefit to patients that was overwhelmingly statistically significant and the results will be revealed for the first time at ESC Congress.

Results from other major trials will be presented, including the SOLID-TIMI 52 trial of the PLA2 inhibitor darapladib. Previous studies have reported its effects in stable coronary artery disease but this is the first trial in myocardial infarction.

Innovative treatment approaches featured in the hot lines include vagal stimulation for systolic heart failure (NECTAR-HF), nitric oxide inhalation to reduce reperfusion injury in STEMI (NOMI) and the novel anti-Xa rivaroxaban for cardioversion (X-VERT).

Professor Fox said: “Several of these trials are really going to change clinical practice and our approaches to managing patients. There will also be a number of important clinical trial updates and big registries that are also going to influence practice.”

He added: “Delegates will have more opportunities to challenge speakers this year by posting questions from their smart phones or tablets. This is the first time we have ever done that and it will enable journalists to hear in real time what the burning issues are in these sessions.”

For more information, see the Congress schedule at http://spo.escardio.org/default.aspx?eevtid=69&days=&topics=&types=11505&rooms=&freetext=&sort=1&page=1&scroll=0&showResults=True&nbPerPage=20

Published on: August 5, 2014

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.